Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 11/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.37 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15914611 | 0.96 | SLC2A1 (0.46) | SLC2A1CYP3A4MKNK1MKNK2NR1I3 | |
| SCHEMBL15914937 | 0.96 | SLC2A1 (0.46) | SLC2A1CYP3A4MKNK1MKNK2NR1I3 | |
| SCHEMBL15914471 | 0.88 | SLC2A1 (0.52) | SLC2A1CYP3A4SLC2A2TOP2ASLC2A3 | |
| SCHEMBL15914747 | 0.85 | SLC2A1 (0.39) | SLC2A1CYP3A4MKNK1MKNK2HRH4 | |
| SCHEMBL15914574 | 0.85 | SLC2A1 (0.39) | SLC2A1CYP3A4MKNK1MKNK2HRH4 | |
| SCHEMBL15915056 | 0.83 | MKNK1 (0.38) | SLC2A1CYP3A4MKNK1MKNK2HRH4 | |
| SCHEMBL15914729 | 0.83 | CYP3A4 (0.36) | SLC2A1CYP3A4MKNK1MKNK2HRH4 | |
| SCHEMBL15914073 | 0.83 | MKNK1 (0.46) | SLC2A1CYP3A4MKNK1MKNK2HRH4 | |
| SCHEMBL15914885 | 0.83 | HRH4 (0.39) | SLC2A1CYP3A4MKNK1MKNK2HRH4 | |
| SCHEMBL15914583 | 0.82 | CYP3A4 (0.35) | SLC2A1CYP3A4MKNK1MKNK2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | HIF1A, HIF1AN, EGLN3 | SLC2A1 1235/4885CYP3A4 1281/4885MKNK1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.